Google-backed Isomorphic Labs delays clinical trial timeline
Tweet
Share
E-mail
Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026. REUTERS/Denis Balibouse
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
The comments, made at an event at the World Economic Forum in Davos, Switzerland, signal a delay in the Google-backed startup's ambitions.
Hassabis had said last year the company would have AI-designed drugs in clinical trials by the end of 2025.
Companies have been increasingly touting the real-world applications of AI, where the technology can be used to speed up research and development and shorten drug discovery timelines in the healthcare sector.
Isomorphic was founded in 2021 as a spin-off from Alphabet's AI research subsidiary, Google DeepMind, which is headed by Hassabis.
One of DeepMind and Hassabis' most celebrated breakthroughs was AlphaFold, an AI program that can predict protein structures.
Isomorphic last year raised $600 million in its first-ever external funding round led by Thrive Capital.
(Reporting by Jeffrey Dastin and Deborah Sophia; Editing by Shreya Biswas)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qatar says citizen killed from shrapnel due to 'military operations'
- BIS says debt, AI boom and fragilities raise global risks
- Migrants in US on temporary status should seek permanent residence or leave, Homeland Secretary says
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
